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Abstract: 18F-FDG PET/CT positron emission tomography studies (FDG-PET) have shown similar cortico-limbic 
metabolic dysregulation in bipolar disorder and schizophrenia, with hypoactive prefrontal cortex coupled with hyperactive 
anterior limbic areas. However, it is not clear whether white matter metabolism connecting these regions is differently 
affected in the two disorders. Forty eight patients with schizophrenia mean age ± S.D] 31.6 ± 7.8 and 56 patients with 
bipolar disorder [mean age±S.D] 46.2 ± 8.9 underwent an 18F-FDG PET/CT scan. Normalized datasets the two groups 
of patients were compared on a voxel-by-voxel basis using a two-sample t statistic test as implemented in SPM8, and 
adding age as covariate. Group differences were assessed applying a threshold of p<0.0005. White matter metabolic 
rates significantly differed between schizophrenia and bipolar disorder, whereas no differences were shown for cortical 
activity. This is the first 18F-FDG PET/CT to our best knowledge, directly comparing subjects with schizophrenia to those 
with bipolar disorder. It reports decreased activity in the center of large fronto-temporal and cerebellar white matter tracts 
in patients with schizophrenia in respect to those with bipolar disorder. This feature may characterize and differentiate 
the regional brain metabolism of the two illnesses. 
Keywords: Schizophrenia, Bipolar illness, Mania, Depression, White matter, Cortical, Brain, Imaging, 18F-FDG 
PET/CT. 
1. INTRODUCTION 
Functional neuro imaging studies with F-18 fluoro-
deoxyglucose based Positron emission tomography( 
FDG-PET) have demonstrated a possible cortico-limbic 
metabolic dysregulation in bipolar disorder with 
features of hypermetabolism involving the limbic 
regions (anterior temporal cortex, parahippocampal 
gyrus,cingulate region and amygdala) accompanied by 
hypometabolism in the prefrontal cortex (i.e., 
dorsolateral prefrontal cortex (DLPFC) and anterior 
cingulate) [1]. The glucose metabolism has been 
correlated with cognitive, attention and memory deficits 
in such patients with manic -depressive phases;even 
during euthymic phases [2, 3].A recent meta analyses 
on functional neuro imaging studies with a large 
volume of patients with bipolar disorder and normal 
controls, also confirmed a possible underlying anterior 
paralimbic dysregulation [4]. However, multiple studies 
on functional neuro imaging in schizophrenic patients 
have also demonstrated prefrontal and anterior 
cingulate hypo-metabolism [5-11]. In addition, posterior 
limbic, amygdalar, basal ganglial, and temporal hyper 
metabolism has been observed in schizophrenia [9, 
12]. Similar findings of temporal lobe hyper perfusion 
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and cortical hypoperfusion have been described in 
functional and contrast enhanced MRI in bipolar [13] 
and schizophrenic patients. [14] Thus it becomes 
difficult to differentiate between the two conditions 
based on FDG PET as a similar prefronto-limbic 
dysregulation might characterize the two disorders. A 
progressive decrease in pre-frontal activity in 
schizophrenia and bipolar disorder could result in a 
loss of inhibition or modulatory control over the deeper 
limbic structures, which would as a corollary show 
increased activation [15]. As there is an overlap of 
clinical features between the two conditions, it would be 
illuminative to identify contributory imaging features to 
differentiate between schizophrenia and bipolar illness. 
Studies have revealed widespread abnormalities 
characterized by a lower fractional anisotropy 
neuroanatomically associated with localized reduced 
grey matter in the schizophrenic group. The grey 
matter changes can either be interpreted as the result 
of a locally reduced cortical thickness or as a 
manifestation of different patterns of gyrification. There 
was a widespread reduction of anisotropy in the white 
matter, especially in the corpus callosum. It is 
speculated that the anisotropy changes relate to the 
functional changes in brain connectivity that are 
thought to play a central role in the clinical expression 
of the disease. The distribution of grey matter changes 
are usually consistent with clinical features of the 
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disease. The metabolic rates of white matter 
connections between the (hypo-active) prefrontal 
regions and the (hyperactive) limbic structures and 
their potential role in specific diseases have not been 
delineated yet. Only two prior PET studies have 
hypothesized and investigated altered fronto-limbic 
connectivity based on altered anterior–posterior 
metabolism in both schizophrenia and bipolar disorder 
[16, 17]. 
In this study we compared brain metabolism with 
18F-FDG PET/CT in a sizeable population composed 
by either schizophrenia or bipolar disorder patients in 
order to directly compare cortical and white matter 
metabolism characterizing the two disorders. 
2. METHODS 
2.1. Subjects 
Forty-eight patients with schizophrenia and 56 
patients with bipolar disorder, who were referred for 
F-18 FDG PET CT of the brain was included in the 
study. Demographic data as well as other disease 
related parameters are given in Table 1.The study was 
cleared by the Institutional review board and written 
informed consent was obtained from all the patients. In 
patients who were considered incompetent to give 
consent, the same was obtained from their spouse, 
parents or immediate relative who was responsible for 
the patients care. 
Inclusion criteria were as follows: current diagnosis 
of schizophrenia and bipolar disorder according to the 
DSM-IV-TR diagnostic criteria [American Psychiatric 
Association (2000). Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition: DSM-IV-TR®. 
American Psychiatric] 
And duration of untreated illness not longer than 5 
years. Diagnoses were made using SCID for DSM-IV-
TR Axis I; interviews were conducted by raters with 
extensive experience in administering the SCID. 
Majority of the schizophrenia patients were 
experiencing acute psychosis (14 during their first 
episode), whereas bipolar disorder patients were 
suffering different mood episodes (32 depressed, 9 
manic, and 15 mixed episodes) when referred. 
However, patients were studied with PET when they 
were relatively clinically stable. Patients with 
schizophrenia, were scored with the Positive and 
Negative Syndrome Scale for Schizophrenia (PANSS) 
and had a score of less than 50 at the time of scan. 
Similarly, for those with bipolar disorder, the Hamilton 
Table 1: Patient Characteristics 
Patients Features Patients with Schizophrenia (n = 48) 
Patients with Bipolar Illness 
(n = 56) 
Significance  
+ if p < 0.01 
- if p >0.05 
± if 0.01<p >0.05 
Mean age ± SD(years) 31.6 ± 7.8 46.2 ± 8.9 + 
Sex ( male/ female) 32/16 32/24 - 
Age of onset± SD(years) 24.6 ± 4.1 34 ± 6.7 + 
Duration of illness ± SD(years)  6.8 ± 3.1 12 ± 8.1 - 
Number of hospitalizations 3.1 ± 2.2 2.9 ± 3.5 - 
 
Table 1: Calculated Metabolic Ratios and Standard Deviations 
Patient group Control Group 
 
Mean SD Mean SD 
Frontal/occipital 1.1 0.09 1.02 0.05 
Parietal/occipital  1.07 0.06 1.05 0.05 
Temporal/occipital  0.96 0.05 0.91 0.03 
Thalamus/occipital 0.97 0.04 0.92 0.06 
Striatum/occipital 1.14 0.08 1.08 0.05 
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Depression Rating Scale (HDRS) scores and the 
Young Mania Rating Scale (YMRS) scores had to be 
<8 and <10, respectively. All patients were on 
treatment, i.e., those with schizophrenia were on 
antipsychotics and benzodiazepines and those with 
bipolar disorder were on antipsychotics, mood 
stabilizers, benzodiazepines, and/or antidepressants  
Exclusion criteria included a diagnosis of mental 
retardation, any lifetime history of significant medical or 
neurological illnesses and substance abuse disorder. 
Information concerning socio-demographic variables 
were collected from patients or from their 
parents/relatives. 
2.2. PET Scan 
18F FDG was obtained from a commercial supplier 
after passing the necessary quality control, sterility and 
other parametric testing as mandated internationally. 
The cyclotron was a GE model 16 Mev cyclotron. It 
was obtained in a ready to use formulation, dispensed 
with individual patient doses under sterile and 
apyrogenic condition. 
FDG-PET scanning was performed on a Siemens 
Symbia 6 PET CT scanner. The scanner acquires 63 
contiguous transaxial planes, simultaneously covering 
15.5 cm of the axial field of view. Data acquisition 
follows a standardized protocol established at the 
Department of nuclear medicine at the Kovai Medical 
Centre and Hospital. An intra venous injection of 170 
MBq (F-18) FDG was given to each patient after 
overnight fasting and checking of fasting blood sugar 
levels. This is followed by an uptake period of 30 to 45 
minutes during which time patient is placed in a dark 
room with no visual or auditory stimuli and encouraged 
to relax. Each patient is then scanned with eyes closed 
in a moderately light environment. The head of the 
patient is fixed in a head holder and adequately 
positioned in the gantry. Acquisition starts with a 
diagnostic CT transmission scan used for subsequent 
attenuation correction. This is followed by the emission 
scan (3 frames, 10 minutes/ frame, 128 x 128 matrix, 
3D acquisition). Images were reconstructed by iterative 
reconstruction using OSEM. Images were corrected for 
scatter and attenuation.  
2.3. PET Analysis 
As first step of the PET image analysis, 
standardized uptake value (SUV-a semi quantitative 
index of the fractional uptake rate of [18F] FDG) maps 
have been derived from the original [18F] FDG images 
by using the following formula: 
SUV = AC ------------------ (FDGdose/ BW) 
Where AC is the activity of -tracer concentration in a 
given voxel [kBq/ml], FDG dose is the injected radio-
tracer dose corrected for residual activity in the syringe 
[MBq], and BW is the body weight [kg]. All the radio-
tracer data were decay corrected before their use. 
The data obtained from the reconstructed PET 
images was transferred to a work station with Scenium 
software (Siemens) which enables one to compare the 
patient data after stereotactic realignment to a 3-
dimensional reference template created from a normal 
database of 102 patients. Deviations from the normal 
database may be assessed on the voxel-level 
evaluating statistical differences using the standard 
deviation criterion. This approach allows one to 
compare the baseline status in different individuals with 
a normal database as well as to assess the intrasubject 
variation in repetitive studies on the same individual. 
Data from the set of 63 ROIs covering the whole brain 
were pooled and combined to separate ROIs for 
frontal, parietal, temporal, occipital cortex as well as 
striatum, thalamus, cerebellum and brainstem. 
Performing a t-test, the ages of the two groups are 
not statistically different (p > 0.05). Several additional 
combinations of covariates were used including age at 
onset, mood state, number of hospitalizations, PANSS, 
HDRS, and YMRS scores, type of medication, drug 
dosages, but none had any significant impact on the 
results.  
Statistics 
All statistics have been calculated using the SPSS 
software package. Ratios between different regions 
and the occipital cortex have been calculated to 
compensate for inter-individual variation of metabolic 
rates. Mean and standard deviation values have been 
calculated for the ratios to describe the distribution of 
the data. Student t tests were used to compare group 
differences between the patient group and the control 
group. 
3. RESULTS 
Regional Metabolic Rates of Glucose 
Metabolic activity corrected for the time of 
administration of 18 FDG was calculated for both 
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patients with schizophrenia and with bipolar disorder 
and compared with the normal population. 
Compared to the normal database population, both 
patient groups demonstrated pre frontal 
hypometabolism with increased hippocampal, 
amygdalar and cingulate metabolism. Patients in acute 
psychosis did demonstrate an associated increased 
dorso-lateral frontal and parietal metabolism while 
subjects with depression demonstrated associated 
basal ganglial and thalamic hypermetabolic pattern; 
though there was no statistically significant association 
noted. Since the standard deviation of the SUV's were 
high in both groups and in all examined regions 
indicating a high inter-individual variation, more 
attention was paid to ratios between brain regions and 
the occipital cortex as reference, referred to as 
‘metabolic ratios’. These also play an important role in 
diagnosing cortical and white matter hypo- or hyper-
metabolic pattern. Table 2 gives an overview of the 
calculated ratios as well as their standard deviation and 
also illustrates differences between the patient groups. 
The mean frontal-occipital, parietal- occipital, 
anterior limbic- occipital, thalamus- occipital, tempero-
occipital and striatum- occipital ratio in both groups of 
patients did not show any statistically significant 
difference. Among all examined metabolic ratios the 
ratios showing the strongest difference between the 2 
patient groups were the Fronto temporal/tempero-
parietal and cerebellar white matter – occipital ratios. 
Looking at the two hemispheres separately revealed all 
together more significantly different metabolic ratios 
between patients and controls in the right hemisphere 
than on the left side. To compare the examined cortex 
areas directly between the two hemispheres, we 
calculated additional right to left ratios for each region, 
which did not show any statistically significant different 
patterns between patients’ and control studies (Table 
2). 
White matter metabolism differed in patients with 
schizophrenia in comparison to those with bipolar 
disorder (p <0.0005), particularly in major frontal, 
parietal, and temporal tracts, as well as in pons and 
cerebellum, even after covarying for medication load. In 
these areas the tracer metabolism of the subjects with 
bipolar disorder was higher than those of patients with 
schizophrenia. In contrast, in our population, there 
were no significant differences in cortical tracer 
metabolism in individuals with schizophrenia or bipolar 
disorder.  
4. DISCUSSION 
Our study is an initial attempt to directly compare 
the resting regional metabolism of schizophrenia to that 
of bipolar disorder and it shows decreased activity in 
the white matter tracts predominantly in the fronto-
temporal, tempero-parietal and cerebellar regions in 
patients with schizophrenia. We could not find any 
statistically significant difference in the cortical 
Table 2: Calculated Metabolic Ratios and Standard Deviations 
Schizophrenia Group Bipolar illness Group 
 
Mean SD Mean SD 
Frontal/occipital 0.5 0.09 0.4 0.05 
Parietal/occipital  1.07 0.06 1.05 0.05 
Anterior limbic/occipital 1.3 0.04 1.2 0.02 
Temporal/occipital  0.96 0.05 0.91 0.03 
Thalamus/occipital 1.08 0.04 1.14 0.06 
Striatum/occipital 1.01 0.08 1.08 0.05 
FT WM/occipital 0.4 0.03 0.97 0.1 
TO WM /occipital 0.5 0.05 1.01 0.08 
Cerebellar WM/occipital 0.3 0.04 0.95 0.06 
FT: Fronto- temporal, TP: Tempero – parietal, WM: white matter 
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metabolic patterns between the two patient groups, 
which is in conformity with multiple earlier reports, and 
PET literature which were summarized earlier. 
A previous study has reported altered and reduced 
white matter metabolic rates in schizophrenia [18] and 
another study by Altamura et.al has suggested 
significant difference between schizophrenic and 
bipolar subjects with regards to white matter metabolic 
rates [17]. Our study demonstrates a similar picture of 
consistent, confluent hypometabolism involving large 
white matter tracts, more pronounced in schizophrenia. 
Similarly a common finding of frontal hypometabolism 
with relative sparing or hypermetabolism of posterior 
cingulate region in both schizophrenia and bipolar 
illnesses are also similar to previous studies. 
Multiple MRI studies have also demonstrated 
abnormalities in brain connectivity, shown by increased 
rates of white matter hyperintensities, regional 
structural alterations and water diffusion impairments, 
in both disorders [19-23]. The most commonly reported 
impairments have been in the frontal and temporo-
parietal longitudinal and inter-hemispheric tracts [24-
27] along with cerebellum and pons [28-32]. It is 
interesting to note that , such white matter impairments 
appear to be more severe and generalized in 
schizophrenia in respect to bipolar disorder [33, 34], 
with more pertinent links to genetics and molecular 
infiltrates.[35, 36]. Consequently it is possible that the 
variance in white matter metabolism observed in the 
two disorders could be due to underlying distinctive 
structural connectivity alterations. Our study contributes 
significant functional and metabolic correlation to the 
premise that fronto-limbic and cerebellar white matter 
activity may be differentially affected in schizophrenia 
and bipolar disorder, and FDG PET could serve in 
characterizing the two illnesses. Thus, the finding of 
similar cortical metabolic pattern in the two disorders 
could also strengthen the ongoing debate concerning 
the Kraepelinian dichotomy of the two illnesses [37]. 
Hypotheses concerning the changes in white matter 
function, structure and metabolism deal propose 
underlying deficits in neuronal circuits, accelerated and 
increased tissue damage, impaired axon laying and 
packing density as well as neuro chemical alterations. 
Post mortem studies in schizophrenia and bipolar 
disorder have demonstrated at the microscopic level, 
lowered density of oligodendroglial cells due to 
apoptosis and necrosis, particularly in the pre-frontal 
cortex and cingulate white matter contributing to 
underlying cortico-limbic disconnectivity [38, 39]. 
Oligodendrocytes have been reported to have a trophic 
influence on neurons and thus, could play a key role in 
inducing altered neuronal connectivity and atrophy in 
these disorders [40]. Moreover genetic defects 
contributing to deficits in the expression of 
oligodendrocyte and myelin have been observed in 
both schizophrenia and bipolar disorder [41, 42], 
potentially explaining the presence of fewer 
oligodendrocytes. As glucose is crucial for sustaining 
neuron–glia interaction and synaptic plasticity, such as 
for the GABAergic and glutamatergic systems, glucose 
consumption and 18FDG uptake analysis could be 
considered as an indirect and associated marker of 
neural tract integrity. Summarizing these findings, 
altered white matter metabolism may play a crucial role 
for the patho-physiology of these disorders, potentially 
accompanying the above mentioned alterations of 
oligodendrocyte viability [43, 44].  
Conclusion: Our study suggests that altered white 
matter activity might serve as a potential biomarker 
helping in separating schizophrenia and bipolar 
disorder. Functional and neuro imaging features , 
exploring similarities and differences in cortical and sub 
cortical metabolic patterns can lead the way forward in 
further understanding the complex etio-pathogenesis of 
these two disorders and can also correlate with their 
phenotype expression [43, 45 ]. Such similarities in 
cortical metabolism patterns could renew the interest of 
the clinicians regarding the validity of the hypothesis 
that schizophrenia and bipolar disorder can be 
conceptualized as a continuous spectrum of clinical 
phenotypes rather than as distinct categories, in the 
context of the Kraepelinian dichotomy [46, 47].  
Larger PET studies should be undertaken to 
elucidate metabolic changes in schizophrenia and 
bipolar disorders, especially in drug naive subjects at 
their very first consultation if possible, to avoid the 
potential influences of chronicity and medications, and 
compare with age- and gender-matched control 
individuals.  
LIMITATIONS O F THE STUDY 
A significant drawback of the study was that all the 
patients were on regular psychiatric and drug 
treatment. Thus it is difficult to rule out the effects of 
psychotropics. Some of the patients were on 
combination therapy and multiple studies have 
described the underlying functional changes in brain 
metabolism after drug therapy. Thus it is difficult to 
separate out the effects of medication from disease 
patho-physiology in such patients  
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